A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This 3 arm study will compare the efficacy and safety of beta-lactam with that of 'standard
care' in patients with complicated skin and skin structure infections requiring
hospitalization. Patients will be randomized to receive 1)beta-lactam 750mg iv q8h
2)beta-lactam 1500mg iv q8h or 3)'standard care' [PRP (nafcillin or flucloxacillin) or
vancomycin, plus aztreonam or ciprofloxacin]. The anticipated time on study treatment is <3
months and the target sample size is 100-500 individuals.